Our Publications include:

 

Ian Gordon, Carolyn Rutherford, Kelly Makarounas-Kirchmann, Matt Kirchmann.  “Meta-analysis of average change in laboratory-measured HbA1c among people with type 1 diabetes mellitus using the 14 day Flash Glucose Monitoring System”. Diabetes Research and Clinical Practice 164 (2020): 108158.

 

Richard Hellmund, Matt Kirchmann, Kelly Makarounas-Kirchmann.  “Cost Effectiveness of FreeStyle Libre® Flash Glucose Monitoring System from an Australian Health Care Payer Perspective”.  Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2016.

 

Makarounas-Kichmann K., Kirchmann M., Monin N. “Lacosamide for the Treatment of Partial Onset Seizures With or Without Secondary Generalisation: Cost-Effectiveness Analysis on Treating Patients With Lacosamide in Combination With a Non-Sodium Anti-Epileptic Medication”. Value in Health Nov. 2012 Vol 15 (7) pp.A676-677.

 

Makarounas-Kichmann K., Ademi Z, Kirchmann M. “PHARMACEUTICAL BENEFIT ADVISORY COMMITTEE ACCEPTABILITY THRESHOLD RESULTS 2005-2011”. Value in Health Nov. 2012 Vol 15 (7) pp.A622. 

 

Makarounas-Kirchmann K., Kirchmann M., Ademi Z., Stoelwinder J. (2012), “Predictors of successfully listing on the PBS: a 2012 update”, ISPOR, Taipei, Taiwan, September 2012

 

Weller C, Ademi Z, Makarounas-Kirchmann K, Stoelwinder J.(2012)  “Economic evaluation of compression therapy in venous leg ulcer randomised controlled trials: A Systematic Review” Wound Practice and Research 20(1) pp.21-34.

 

Makarounas-Kirchmann K. (2012), “ICER Thresholds in a galaxy far, far away….”, ARCS Conference, Canberra, Australia September 2012

 

Ioannides-Demos LL, Makarounas-Kirchmann K, et al. (2010). "Cost of Myocardial Infarction to the Australian Community A Prospective, Multicentre Survey." Clinical Drug Investigation 30(8): 1-11.

 

Makarounas-Kirchmann K, Glover-Koudounas S, et al. (2009). "Results of a Meta-analysis Comparing the Tolerability of Lercanidipine and other Dihydropyridine Calcium Channel Blockers", Clinical Therapeutics 31(8): 1652-1663.

 

Makarounas-Kirchmann K and Stoelwinder J (2007). “Predicting successful listing of pharmaceuticals on the PBS”, 6th World Congress on Health Economics, iHEA. Coppenhagen, Denmark, July 2007.

 

Makarounas-Kirchmann K (2003). Pharmaceutical Pricing. Pricing Conference, HIR, Singapore.

 

Pratt NL, Beilby JJ, et al. (2001). The Costs of Uncontrolled Hypertension - A Preliminary Overview. 17th International Conference on Pharmacoepidemiology Toronto, Canada.

 

Bishop JF and Macarounas-Kirchmann K (1997). "Pharmacoeconomics of Cancer Therapies." Seminars in Oncology 24(Suppl 19): 106-111.

 

Grobler MP, Macarounas-Kirchmann K, et al. (1997). "A Industry Comment on the 1995 Revised Australian Pharmacoeconomic Guidelines." PharmacoEconomics 9(4): 353-356.

 

Nord E, Richardson J, et al. (1993). "Social Evaluation of Health Care Versus Personal Evaluation of Health States: Evidence on the Validity of Four Health State Scaling Instruments Using Norwegian and Australian Survey Data." International Journal of Health Technology 9: 463-478.

 

Some of the recent projects we have completed include :

  • Identification of market opportunity for a new generic provider.
  • Negotiating with government departments on behalf of one of the most respected OTC suppliers.
  • Positioning a PBS listed medication to achieve a further indication in a new therapeutic area.
  • PBS listing of a novel pharmaceutical preparation for an entirely new treatment process.
  • Preparation of PBAC submissions to remove medications from a Therapeutic Class.
  • Seeking new indications for PBS listed medications.
  • Advising on pricing implications during recent government reforms.
  • Development of a UKPDS based risk engine within a complex Markov Model including Monte-Carlo simulations.